Viking Therapeutics, Inc - VKTX STOCK NEWS

Viking Therapeutics (Nasdaq: VKTX) announced the closing of a public offering of 19,828,300 shares of common stock at $14.50 per share, generating gross proceeds of approximately $287.5 million. The underwriters exercised their option to purchase an additional 2,586,300 shares. Proceeds will fund the continued development of VK2809, VK2735, and VK0214 programs, alongside general research and development. The offering was conducted under an effective shelf registration statement filed with the SEC. Notably, Viking's clinical programs target metabolic and endocrine disorders, with promising developments in treatments for NASH and X-ALD.

Viking Therapeutics, Inc. (NASDAQ: VKTX) has priced its public offering of 17,242,000 shares at $14.50 per share, aiming for gross proceeds of approximately $250 million. The offering is set to close on or about April 3, 2023. Underwriters have a 30-day option to purchase an additional 2,586,300 shares. Funds will support ongoing development of VK2809, VK2735, VK0214, and general research and development. The public offering is conducted under an effective shelf registration statement filed with the SEC. Viking focuses on innovative therapies for metabolic and endocrine disorders, with compounds in active clinical trials.

Viking Therapeutics (Nasdaq: VKTX) announced a proposed underwritten public offering of its common stock on March 29, 2023. The company plans to grant underwriters a 30-day option to purchase up to an additional 15% of shares sold. Viking intends to utilize the net proceeds for the development of its clinical programs, including VK2809, VK2735, and VK0214, as well as for general corporate purposes. The public offering will occur under a shelf registration statement previously filed with the SEC. No assurance is given regarding the completion of the offering or its terms.

Viking Therapeutics (VKTX) has commenced a Phase 1 clinical study of VK2735, an oral formulation of its dual GLP-1 and GIP receptor agonist. This study follows a recently completed Phase 1 trial of a subcutaneous version of VK2735, which showed promising results, including a body weight reduction of up to 7.8% in participants. The Phase 1 trial of the oral formulation aims to assess safety, tolerability, and pharmacokinetics over 28 days in healthy adults. Results from this study are expected in the second half of 2023, and Viking plans to advance to a Phase 2 trial for the subcutaneous formulation focused on obesity treatment.

Viking Therapeutics (NASDAQ: VKTX) announced promising results from its Phase 1 clinical trial for VK2735, a dual GLP-1/GIP receptor agonist aimed at treating metabolic disorders. The trial demonstrated a placebo-adjusted mean weight loss of 6.0% and a total weight loss of 7.8% from baseline over 28 days. VK2735 was found to be safe and well-tolerated, with the majority of adverse events being mild to moderate. A Phase 2 trial targeting obesity is slated for mid-2023, with further dose escalation planned based on these results.

Viking Therapeutics (NASDAQ: VKTX) announced its participation in two investor conferences on March 7, 2023. Brian Lian, Ph.D., CEO, will engage in a fireside chat at the 35th Annual Roth Conference from March 12-14, 2023, at 2:30 p.m. PT on March 13. Additionally, Dr. Lian will present at the Oppenheimer 33rd Annual Healthcare Conference from March 13-15, 2023, at 7:40 a.m. PT on March 14. A live webcast of the Oppenheimer presentation will be available on the Viking website. Viking focuses on developing therapies for metabolic and endocrine disorders, with three compounds in clinical trials, including VK2809 for NASH and VK2735 for metabolic disorders.

Viking Therapeutics (NASDAQ: VKTX) announced its financial results for Q4 2022, reporting a net loss of $19.6 million or $0.26 per share, up from $12.4 million or $0.16 per share in Q4 2021. For the full year, its net loss was $68.9 million, compared to $55.0 million in 2021. The company is advancing its clinical pipeline, with enrollment completed in the Phase 2b VOYAGE trial for VK2809 targeting NASH and fibrosis, data expected in Q2 2023. Viking holds $155 million in cash, providing a solid financial foundation to pursue its clinical milestones and upcoming data releases for various programs, including VK2735 and VK0214.

Viking Therapeutics (NASDAQ: VKTX), a clinical-stage biopharmaceutical company, announced that CEO Brian Lian, Ph.D., will present at the SVB Securities Global Biopharma Conference from February 13-16, 2023. The presentation is scheduled for February 15 at 2:20 p.m. Eastern time and will be conducted virtually. Viking focuses on therapies for metabolic and endocrine disorders and has three compounds in clinical trials, including VK2809 for non-alcoholic steatohepatitis (NASH) and VK2735 for various metabolic disorders. The company holds exclusive rights to five therapeutic programs developed from licensed small molecules.

Viking Therapeutics (NASDAQ: VKTX) will announce its fourth quarter and year-end 2022 financial results on February 8, 2023, after market close. A conference call to discuss the results will follow at 4:30 p.m. ET. The company focuses on developing therapies for metabolic and endocrine disorders and is currently running clinical trials for its compounds VK2809, VK2735, and VK0214. VK2809 is in a Phase 2b study for treating NASH and fibrosis, showing promising results in earlier trials. Interested parties can participate in the call by dialing specified numbers or can access the webcast on Viking's website.